MEDP vs RVTY: Medpace and Revvity compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Medpace is the larger company, worth $17.3B, close to Revvity's $17.3B.
- Medpace grew revenue faster over the last year (+17.2% vs +1.3%).
- Medpace keeps more of each dollar of revenue as operating profit (21.0% vs 12.3%).
- On earnings, Medpace is the cheaper stock (38.2x vs 74.5x).
- Revvity's price assumes faster free cash flow growth: about 12% a year, against 8% for Medpace (reverse DCF).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | MEDP | RVTY |
|---|---|---|
| Market cap | $17.3B | $17.3B |
| Share price | $612.05 | $154.18 |
| Revenue (last fiscal year) | $2.5B | $2.9B |
| Free cash flow (last fiscal year) | $682M | $509M |
| Revenue growth, last year | +17.2% | +1.3% |
| Revenue growth per year, last 5 fiscal years | +22.0% | -13.4% |
| Operating margin | 21.0% | 12.3% |
| Net margin | 17.7% | 8.2% |
| Return on equity | 113.3% | 3.3% |
| P/E (trailing) | 38.2x | 74.5x |
| Price / free cash flow | 25.4x | 34.0x |
| EV / EBITDA | 26.8x | 25.6x |
| FCF growth the price implies | 8.1% | 11.9% |
| Dividend yield | — | 0.18% |
| Debt / equity | 3.74x | 0.67x |
| Fundamental grade | C | D |
| Superinvestors holding it | 5 | 4 |
| Insider purchases, last 12 months | 4 | 0 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Medpace
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $1.1B | $235M | 17.4% |
| 2022 | $1.5B | $351M | 19.1% |
| 2023 | $1.9B | $397M | 17.9% |
| 2024 | $2.1B | $572M | 21.2% |
| 2025 | $2.5B | $682M | 21.1% |
Revvity
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $5.1B | $1.3B | 26.3% |
| 2022 | $3.3B | $594M | 22.4% |
| 2023 | $2.8B | $10M | 10.9% |
| 2024 | $2.8B | $542M | 12.6% |
| 2025 | $2.9B | $509M | 12.5% |
Where the revenue comes from
Medpace · by products, 2025
Oncology$748M30%
Other$745M29%
Metabolic$409M16%
AVAI$255M10%
Central Nervous System$239M9%
Cardiology$135M5%
Revvity · by segments, 2025
Life Sciences$1.4B50%
Diagnostics$1.4B50%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open MEDP in InvestinglyQuestions
Which is bigger, Medpace or Revvity?
Medpace (MEDP), at $17.3B against $17.3B.
Is MEDP or RVTY cheaper?
By trailing P/E, Medpace (38.2x) is cheaper than Revvity (74.5x). A lower multiple can also mean the market expects less growth.
Which grows faster, MEDP or RVTY?
Medpace: revenue grew +17.2% over the last year, against +1.3%.
More comparisons
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.